^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Breast Cancer
    Drug:Ogivri (trastuzumab-dkst) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    Ogivri is a HER2/neu receptor antagonist indicated for...the treatment of HER2-overexpressing breast cancer.
    Secondary therapy:
    docetaxel + doxorubicin hydrochloride + cyclophosphamide; paclitaxel + doxorubicin hydrochloride + cyclophosphamide; carboplatin + docetaxel; paclitaxel
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.

    Excerpt:
    ...Documentation of HER2 gene amplification by fluorescent in situ hybridization (FISH) (as defined by a ratio >2.0) or documentation of HER2-overexpression by immunohistochemistry (IHC) (defined as IHC3+, or IHC2+ with FISH confirmation) based on the sponsor-identified central laboratory prior to randomization....
    Trial ID:
    HERiTAge
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Nanoscale Res Lett
    Title:

    Microwave-Assisted Chitosan-Functionalized Graphene Oxide as Controlled Intracellular Drug Delivery Nanosystem for Synergistic Antitumour Activity

    Published date:
    04/30/2021
    Excerpt:
    ...safety and therapeutic efficacy in HER2-overexpressing BT-474 cells...The combined treatment of ChrGO/adriamycin and trastuzumab in BT-474 cells induced cell cycle arrest and apoptosis, which ultimately led to the death of augmented cancer cells.
    Secondary therapy:
    doxorubicin hydrochloride
    DOI:
    10.1186/s11671-021-03525-y